全文获取类型
收费全文 | 211136篇 |
免费 | 29306篇 |
国内免费 | 6989篇 |
专业分类
耳鼻咽喉 | 1973篇 |
儿科学 | 1602篇 |
妇产科学 | 5267篇 |
基础医学 | 14802篇 |
口腔科学 | 2302篇 |
临床医学 | 17270篇 |
内科学 | 20572篇 |
皮肤病学 | 1390篇 |
神经病学 | 1070篇 |
特种医学 | 6101篇 |
外国民族医学 | 256篇 |
外科学 | 32386篇 |
综合类 | 27684篇 |
现状与发展 | 38篇 |
一般理论 | 3篇 |
预防医学 | 9872篇 |
眼科学 | 250篇 |
药学 | 14912篇 |
134篇 | |
中国医学 | 5131篇 |
肿瘤学 | 84416篇 |
出版年
2024年 | 220篇 |
2023年 | 4442篇 |
2022年 | 6411篇 |
2021年 | 10937篇 |
2020年 | 10924篇 |
2019年 | 9867篇 |
2018年 | 9448篇 |
2017年 | 9832篇 |
2016年 | 10599篇 |
2015年 | 12244篇 |
2014年 | 17926篇 |
2013年 | 17519篇 |
2012年 | 14133篇 |
2011年 | 14368篇 |
2010年 | 10456篇 |
2009年 | 10688篇 |
2008年 | 10956篇 |
2007年 | 10211篇 |
2006年 | 9009篇 |
2005年 | 7374篇 |
2004年 | 6076篇 |
2003年 | 5061篇 |
2002年 | 4293篇 |
2001年 | 3878篇 |
2000年 | 3183篇 |
1999年 | 2637篇 |
1998年 | 2034篇 |
1997年 | 1777篇 |
1996年 | 1435篇 |
1995年 | 1539篇 |
1994年 | 1276篇 |
1993年 | 959篇 |
1992年 | 845篇 |
1991年 | 773篇 |
1990年 | 579篇 |
1989年 | 522篇 |
1988年 | 442篇 |
1987年 | 391篇 |
1986年 | 312篇 |
1985年 | 388篇 |
1984年 | 306篇 |
1983年 | 203篇 |
1982年 | 209篇 |
1981年 | 197篇 |
1980年 | 176篇 |
1979年 | 117篇 |
1978年 | 77篇 |
1977年 | 62篇 |
1976年 | 59篇 |
1975年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
1.
2.
3.
Marco N. Iannone Stefano Stucchi Elia A. Turolla Chiara Beretta Samuele Ciceri Clizia Chinello Lisa Pagani Sergio Todde Patrizia Ferraboschi 《Journal of labelled compounds & radiopharmaceuticals》2022,65(3):48-62
In the last decade, the development of new radiopharmaceuticals for the imaging and therapy of prostate cancer has been a highly active and important area of research, especially focusing on the prostate-specific membrane antigen (PSMA), an antigen which is upregulated in prostate, as well as in other tumor cells. A large variety of PSMA ligands have been radiolabeled, to date. Among the various derivatives, PSMA-617 resulted to be one of the most interesting in terms of interaction with the antigen and clinical properties, and its lutetium-177 labeled version has recently been approved by regulatory agencies for therapeutic purposes. For this reasons, the radiolabeling with fluorine-18 of a PSMA-617 derivative might be of interest. Beside other methodologies to radiolabel macromolecules with fluorine-18, the “click-chemistry” approach resulted to be very useful, and the copper-catalyzed azide-alkyne cycloaddition (CuAAC) is considered one of most efficient and reliable. This paper proposes the synthesis of a suitable precursor for the radiolabeling with fluorine-18 of a new PSMA-617 derivative. The whole radiosynthetic procedure has been fully automated, and the final product, which proved to be stable in plasma, has been obtained with radiochemical yield and purity suitable for subsequent preclinical studies. 相似文献
4.
胃癌作为临床最常见的肿瘤之一,常因确诊疾病较晚而影响治疗效果,胃镜活检后的病理虽然作为确诊的金标准,但是由于此方式过程痛苦,操作复杂,费用较高,且具有侵入性,可能会导致患者拒绝操作而难普及于临床,因此积极找寻胃癌有效的监测指标十分必要。近年来,很多学者研究维生素与胃癌的相关关系,并试图通过摄取某些维生素降低胃癌发生率,延缓病情及改善预后,也有通过检测血清中维生素的水平给早期胃癌的诊断提供帮助。本文就同型半胱氨酸、维生素D、维生素C、维生素E、维生素B12及叶酸在胃癌中的作用机制,及其在血清中水平与胃癌关系的相关研究进展进行简要综述,为临床胃癌诊疗提供新思路。 相似文献
5.
Kevin Kyung Ho Choi Santosh Sanagapalli 《World journal of gastrointestinal oncology》2022,14(3):568-586
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett’s in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett’s with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett’s by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett’s is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations. 相似文献
6.
Alicia C. McDonald PhD MPH Jeremy Gernand PhD Nathaniel R. Geyer DrPH Hongke Wu MD MPH Yanxu Yang MPH Ming Wang PhD 《Cancer》2022,128(9):1832-1839
7.
8.
《European journal of surgical oncology》2022,48(4):783-788
BackgroundInvestigation of lymph node micrometastasis (mN) of gastric cancer has been focused on either T1 disease or T1-4N0 disease. Yet, it is unclear whether standard management algorithm toward poorly differentiated gastric cancer (PDGC) is more vulnerable to existence of mN, given its inherently biological aggressiveness, as compared with other histological types.Patients and methodsA surgical series (n = 3456) of gastric cancer categorized by histological differentiation was enrolled to analyze survival stratification. Of them, a cohort of T1-T4 N0 PDGC (n = 100) were subjected to cytokeratin immunohistochemistry, a surrogate of mN.ResultsCancer-specific survival by AJCC8 staging system could be nicely differentiated in both well-/moderately differentiated and signet ring cell types, while those between stage IA versus IB (p = 0.105), and stage IB versus IIA (p = 0.141) in PDGC could not. Thirteen (13%) out of 100 node-negative PDGC cases exhibited mN, with 5, 2, 5 and 1 cases occurring in T1, T2, T3, and T4 stage, respectively, without identifiable contributing factors. Prognostic performance of AJCC8 working upon PDGC became more discriminative by incorporating mN, as hazard ratio of stage IIIC referenced to stage IA increased from 43 to 78.ConclusionDefective discriminative survival of PDGC by standard staging algorithm prompted us to survey mN occurring in T1-T4N0 PDGC. The prognostic performance of AJCC8 working upon PDGC was enhanced by incorporating mN. As so, we recommend documentation of mN exclusively on node-negative PDGC that helps unveil stage migration phenomenon and switch to appropriate adjuvant therapy in need. 相似文献
9.
10.